PANACENT Trademark

Trademark Overview


On Monday, April 8, 2024, a trademark application was filed for PANACENT with the United States Patent and Trademark Office. The USPTO has given the PANACENT trademark a serial number of 98488875. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, April 1, 2025. This trademark is owned by Panacent Bio Inc.. The PANACENT trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research services for both medical and non-medical purposes based on transcriptomics, genomic, and proteomic analyses and providing custom consulting services related thereto; Scientific research services for both medical and non-medical purposes, namely analyses and providing custom consulting services based on single-cell omics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Scientific research services for analysis of clinical trial data providing custom consulting services related thereto; Scientific research services for identification of therapeutic target and pathways based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data, and providing custom consulting services related thereto; Software as a service (SaaS) services f...
panacent

General Information


Serial Number98488875
Word MarkPANACENT
Filing DateMonday, April 8, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, April 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 4, 2025

Trademark Statements


Goods and ServicesScientific research services for both medical and non-medical purposes based on transcriptomics, genomic, and proteomic analyses and providing custom consulting services related thereto; Scientific research services for both medical and non-medical purposes, namely analyses and providing custom consulting services based on single-cell omics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Scientific research services for analysis of clinical trial data providing custom consulting services related thereto; Scientific research services for identification of therapeutic target and pathways based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data, and providing custom consulting services related thereto; Software as a service (SaaS) services featuring software for AI-based identification, collection, curation, and presentation of single-cell data from third party sources; Software as a service (SaaS) services featuring software for AI-based training and generation of translational systems biology models using single-cell data from third party sources, and data from bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for AI-based integration and analysis of single-cell data from third party sources and clinical data, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for AI-based analysis of single-cell omics, proteomics, transcriptomics, and genomics; Software as a service (SaaS) services featuring software for identification of therapeutic and cellular pathway target; Software as a service (SaaS) services featuring software for development of novel therapeutic compounds; Software as a service (SaaS) services featuring software for prediction of drug responses and treatment optimization for individual patients based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data and patient-specific data; Software as a service (SaaS) services featuring software for patient stratification based on disease progression or recurrence risk identifying those who may benefit from more aggressive treatment or monitoring based on molecular single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for matching patients with clinical trials based on single-cell omics, proteomics, genomics transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 7, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePanacent Bio Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMiddletown, DE 19709

Party NamePanacent Bio Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMiddletown, DE 19709

Trademark Events


Event DateEvent Description
Monday, April 8, 2024NEW APPLICATION ENTERED
Tuesday, October 22, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, September 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 21, 2024ASSIGNED TO EXAMINER
Tuesday, October 22, 2024NON-FINAL ACTION E-MAILED
Tuesday, October 22, 2024NON-FINAL ACTION WRITTEN
Tuesday, January 7, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 7, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 7, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 8, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 29, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 4, 2025PUBLISHED FOR OPPOSITION
Tuesday, February 4, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 1, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT